<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Humanized CD137 Models for Preclinical Drug Development

PD-1/PD-L1 checkpoint inhibitors have achieved huge clinical success (and drug approval) across a range of cancer types. However, overall response rates to these agents remains low.